Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of ND4 LHON subjects treated with GS010
2017-002153-11Phase 3Completed
- Sponsor
- GenSight Biologics
- Start
- Nov 2017
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lenadogene nolparvovec in Leber hereditary optic neuropathy (LHON), sponsored by GenSight Biologics. Started Nov 2017; status: completed.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on 2017-002153-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002153-11.